Key facts
- This page summarizes Ryan D. Maynard's Form 4 filing for IOVANCE BIOTHERAPEUTICS, INC. (IOVA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jun 2022, 20:02.
Ryan D. Maynard - 31 May 2022 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
- Reporting relationship
- Director
- Issuer ticker
- IOVA
- Reported as of
- 31 May 2022
- Net transaction value
- +$50,588
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2022, 20:02:55 UTC
- Prior SEC filing
- 01 Jul 2021
- Next SEC filing
- 14 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ryan Maynard
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ryan D. Maynard filed Form 4 for IOVANCE BIOTHERAPEUTICS, INC. (IOVA) on 02 Jun 2022.
Change
- Previous filing in this sequence was filed on 01 Jul 2021.
- Current net transaction value: +$50,588.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IOVA
transaction
Common Stock
Purchase
- Transaction value
- $50,588
- Shares
- +7,500
- Change %
- Price
- $6.74
- Shares after
- 7,500
- Date
- 31 May 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.